This therapeutic idea focuses on optimizing AAV (Adeno-Associated Virus) serotypes and delivery strategies for enhanced central nervous system (CNS) targeting in neurodegenerative disease gene therapy. While AAV vectors are widely used for CNS gene delivery, current serotypes face limitations in transduction efficiency, blood-brain barrier (BBB) penetration, and neuronal subtype specificity. This approach combines novel serotype engineering, route-of-administration optimization, and targeted capsid modification to achieve superior CNS delivery for therapeutic genes targeting AD, PD, ALS, and FTD.
| Dimension | Score | Rationale |
|---|---|---|
| Novelty | 8 | Novel AAV engineering approaches not yet in clinic; focuses on next-generation capsids |
| Mechanistic Rationale | 9 | Direct delivery of therapeutic genes; addresses fundamental delivery bottleneck |
| Root-Cause Coverage | 7 | Enables gene replacement/silencing for monogenic forms; supports multi-target approaches |
| Delivery Feasibility | 7 | Intrathecal and intravenous delivery with BBB-crossing capsids feasible |
| Safety Plausibility | 8 | AAV has strong safety profile; integration-deficient variants reduce insertional mutagenesis |
| Combinability | 9 | Can combine with RNA-targeting, gene editing, and protein replacement approaches |
| Biomarker Availability | 6 | Therapeutic gene expression can be monitored via CSF and PET tracers |
| De-risking Path | 7 | Non-human primate studies can validate transduction and safety |
| Multi-disease Potential | 10 | Platform applicable to AD, PD, ALS, FTD, Huntington's, and other CNS diseases |
| Patient Impact | 8 | Single-administration potential for sustained therapeutic benefit |
Total: 76/100
Delivery Innovation + Novel Target
| Disease | Coverage Score | Rationale |
|---|---|---|
| Alzheimer's Disease | 8 | Delivery of APOE, BACE1 siRNA, neurotrophic factors |
| Parkinson's Disease | 9 | Delivery of GDNF, AADC, LRRK2 siRNA, alpha-synuclein silencers |
| ALS | 8 | Delivery of SOD1 ASO, C9orf72-targeting, neurotrophic factors |
| FTD | 8 | Delivery of GRN, MAPT-targeting, TDP-43 modulators |
| Aging | 7 | Anti-aging gene delivery (klotho, SIRT1) for cognitive preservation |
The therapeutic strategy involves using next-generation AAV capsids engineered through:
| Disease | Target Gene/Approach | Delivery Strategy |
|---|---|---|
| AD | APOE4→APOE3 conversion | AAVrh.10hAPOE3 |
| AD | BACE1 knockdown | AAV9-miRNA-BACE1 |
| PD | GDNF overexpression | AAV2-GDNF |
| PD | SNCA silencing | AAV9-shRNA-SNCA |
| PD | LRRK2 inhibition | AAV9-CRISPRi-LRRK2 |
| ALS | SOD1 silencing | AAVrh.10-SOD1-ASO |
| ALS | C9orf72 reduction | AAV9-C9orf72-ASO |
| FTD | PROGRANULIN rescue | AAVrh.10hGRN |
This delivery platform can be combined with: